SS-31 10mg
Mitochondria-Targeting Peptide for Cardiac and Aging Research
SS-31 (Elamipretide/MTP-131) is a mitochondria-targeted tetrapeptide that binds cardiolipin, stabilizes cristae structure, and dramatically restores mitochondrial function in aging, ischemia, and disease models. It is in Phase 3 trials for Barth syndrome.
Mitochondria-Targeting Peptide for Cardiac and Aging Research
SS-31 concentrates in the inner mitochondrial membrane via its cationic charge and aromatic residues, binding cardiolipin to preserve cristae architecture, reduce ROS, and restore electron transport efficiency in damaged mitochondria.
As one of the most studied compounds in the recovery & healing research space, SS-31 has attracted sustained scientific interest across Mitochondrial biology research, Cardiac protection studies, Aging and longevity research. Peer-reviewed evidence indicates that phase 3 trials for Barth syndrome cardiac outcomes, which has positioned SS-31 as a reference standard for researchers exploring mitochondrial biology research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
SS-31 Documented Benefits: 4 Documented Mechanisms
Mitochondrial Rescue
Restores cristae structure and electron transport chain function in aging and damaged mitochondria.
Cardiac Protection
Dramatically reduces infarct size in ischemia-reperfusion models; in clinical trials for heart failure.
ROS Reduction
Reduces mitochondrial superoxide production by improving electron transport efficiency.
Aging Reversal
Restores mitochondrial function in aged animals, improving exercise capacity and metabolic health.
How SS-31 Works: Molecular Mechanism & Pathway
Cationic tetrapeptide concentrating in the inner mitochondrial membrane, binding cardiolipin to stabilize cristae architecture and restore Complex I-IV electron transport efficiency.
The 4 primary research pathways identified for SS-31 — Mitochondrial Rescue, Cardiac Protection, ROS Reduction — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that reduces heart failure progression in animal models, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, SS-31's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
SS-31 is routinely studied alongside NAD+ and MOTS-c in recovery & healing-focused compound panels. Researchers investigating mitochondrial biology research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that restores mitochondrial function in aging mice within 8 hours has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All SS-31 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Phase 3 trials for Barth syndrome cardiac outcomes
- Reduces heart failure progression in animal models
- Restores mitochondrial function in aging mice within 8 hours
Ideal For
- Mitochondrial biology research
- Cardiac protection studies
- Aging and longevity research
- Ischemia-reperfusion studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on SS-31. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Phase 3 trials for Barth syndrome cardiac outcomes
Reduces heart failure progression in animal models
Restores mitochondrial function in aging mice within 8 hours
Third-Party Verified Every Batch
Each vial of SS-31 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
